Advertisement
News
Subscribe to MDT Magazine News

Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes

May 26, 2011 6:34 am | by Bio-Medicine.Org | Comments

CHADDS FORD, Pa., May 26, 2011 /- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) today announced a private offering of $700 million aggregate principal amount of senior unsecured notes. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by...

TOPICS:

Lpath CEO, Scott Pancoast, to Present Live Online at RetailInvestorConferences.com on June 2 at 1 PM EDT

May 26, 2011 6:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, will present on RetailInvestorConferences.com on June 2, 2011 at 1:00 PM EDT. Lpath's president and CEO, Scott Pancoast, will discuss the company's progress, including status updates...

TOPICS:

American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit

May 26, 2011 6:34 am | by Bio-Medicine.Org | Comments

WESTON, Fla., May 26, 2011 /- American Scientific Resources, Inc. (OTCQB: ASFX) (the "Company") today announces that the Company, Kidz-Med, Inc. and Sanomedics International Holdings, Inc., and its affiliates, have each agreed to withdraw the claims brought in the United States District...

TOPICS:
Advertisement

Elekta and ScandiDos Sign Distributor Agreement for Pre-Treatment Verification Tool for Radiation Therapy

May 26, 2011 6:34 am | by Bio-Medicine.Org | Comments

CRAWLEY, England, May 26, 2011 /- Elekta and ScandiDos AB have entered into a non-exclusive global agreement to distribute ScandiDos's Delta4PT quality assurance (QA) tool. Delta4PT can be used with Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT)...

TOPICS:

Rigel Announces Pricing of Public Offering of Common Stock

May 26, 2011 6:34 am | by Bio-Medicine.Org | Comments

SOUTH SAN FRANCISCO, Calif., May 26, 2011 /- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ), today announced the pricing of its previously announced underwritten public offering of 16,300,000 shares of its common stock, offered at a price of $8.00 per share to the public. The gross proceeds...

TOPICS:

Within3 Adds Chief Financial Officer

May 26, 2011 5:34 am | by Bio-Medicine.Org | Comments

CLEVELAND, May 26, 2011 /- Within3 announced that Brian Catlett has joined the company in the newly created position of Chief Financial Officer. He will be a key member of Within3's executive team (including corporate strategic planning) for the company that is the leading provider of...

TOPICS:

Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference

May 26, 2011 5:31 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., May 26, 2011 /- Masimo (NASDAQ: MASI ) today announced that its management is scheduled to present at the Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in Rancho Palos Verdes, California, on Thursday, June 9, 2011, at 8:40 a.m. Pacific Time.  A...

TOPICS:

Nix the Knife

May 26, 2011 5:31 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Patients looking for a quick nip/tuck but don't want to go under the knife now have a way to snap sagging skin into place and outsmart stubborn body fat.  This month, The Body Contouring Center at the renowned JUVA Skin & Laser Center in New York has...

TOPICS:
Advertisement

First-Year Radiologists Making $350,000

May 26, 2011 4:35 am | by Diagnostic Imaging | Comments

The median starting salary for diagnostic radiologists in 2010 was $288,000, according to the just-released Placement Starting Salary Survey: 2011 Report Based on 2010 Data from the Medical Group Management Association.

TOPICS:

ColonCAD Cleared by FDA

May 26, 2011 4:35 am | by Diagnostic Imaging | Comments

Medicsight now has FDA 510(k) clearance to market ColonCAD, a computer-aided detection system to aid in CT colonography.

TOPICS:

Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Requir...

May 26, 2011 4:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS...

TOPICS:

Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

May 26, 2011 4:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market...

TOPICS:

Reportlinker Adds Time and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Management

May 26, 2011 4:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Time and Cost Reduction in Clinical Trials- Outsourcing and IT to Optimize Patient Recruitment, Logistics, Data and Site Management...

TOPICS:

All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated

May 26, 2011 4:34 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., May 26, 2011 /- Pharmasset, Inc. (Nasdaq: VRUS ) announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY ) NS5A replication...

TOPICS:

Reportlinker Adds Advances in Drug-Diagnostic Co-Development

May 26, 2011 4:34 am | by Bio-Medicine.Org | Comments

NEW YORK, May 26, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Advances in Drug-Diagnostic Co-Development...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading